title: [Thrombocytopenia induced by type II heparin and myocardial infarct: 2 case reports].
abstract: Heparin-induced thrombocytopenia (HIT) type II is an acquired thrombophylic state and life-threatening immune complication of a heparin treatment mainly clinically manifested by marked thrombocytopenia, frequently by arterial and venous thrombosis, and sometimes by skin changes. Functional assay as heparin aggregation test and 14C-serotonin release assays are used in diagnostics as well as antigen assays of which detection tests for heparin-platelet factor 4 antibodies are most frequently used. Considering the fact that there is no single reliable assays for HIT II detection available, sometimes it is necessary to combine both of the above-mentioned types of assays. We present the case of a 57-year-old patient with an acute anterior myocardial infarction with cardiac insufficiency of III and IV degree according to Killip, recurrent ventricular fibrillation and diabetes mellitus type II developing thrombocytopenia to 37 x 10(9)/l accompanied with typical skin changes. The diagnosis was confirmed by the heparin aggregation test. The second patient aged 70 undergoing the treatment for anteroseptal myocardial infarction and reinfarction of the inferior wall complicated by a cardiogenic shock and acute right bundle branch block developed thrombocytopenia 59 x 10(9)/l on the third day of the heparin therapy, with the remark that he had received a heparin therapy during the first infarction as well. Antibodies against heparin-platelet factor 4 were detected by particle gel ID-HPF4 immuno-assay. In both patients, the disease had a lethal outcome despite all then available therapeutic measures applied. Further on we discuss advantages of certain types of tests, a therapy doctrine, need for urgent therapeutic measures, inclusive of the administration of antithrombins, avoidance of harmful procedures like low-molecular-weight heparins administration and prophylactic platelet transfusion as well as preventive measures.
authors.affiliation: Institut za kardiovaskularne bolesti Klinicki centar Srbije Pasterova 2, 11000 Beograd.
authors.forename: Nabojsa
authors.initials: N
authors.lastname: Antonijević
authors.forename: Milica
authors.initials: M
authors.lastname: Stanojević
authors.forename: Jovan
authors.initials: J
authors.lastname: Perunicić
authors.forename: Milan
authors.initials: M
authors.lastname: Djokić
authors.forename: Danijla
authors.initials: D
authors.lastname: Miković
authors.forename: Mirjana
authors.initials: M
authors.lastname: Kovac
authors.forename: Predrag
authors.initials: P
authors.lastname: Miljić
authors.forename: Rajko
authors.initials: R
authors.lastname: Milosević
authors.forename: Branka
authors.initials: B
authors.lastname: Terzić
authors.forename: Zorana
authors.initials: Z
authors.lastname: Vasiljević
mesh_terms: D000368:Aged; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis
chemical_list: D005343:Fibrinolytic Agents; D006493:Heparin